Public Employees Retirement Association of Colorado Sells 980 Shares of Repligen Co. (NASDAQ:RGEN)

Public Employees Retirement Association of Colorado reduced its position in Repligen Co. (NASDAQ:RGEN) by 0.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 111,883 shares of the biotechnology company’s stock after selling 980 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Repligen were worth $20,578,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Retirement Systems of Alabama boosted its position in Repligen by 0.4% during the 4th quarter. Retirement Systems of Alabama now owns 65,032 shares of the biotechnology company’s stock worth $11,693,000 after buying an additional 288 shares during the period. Evoke Wealth LLC acquired a new position in shares of Repligen in the 4th quarter worth approximately $1,955,000. International Assets Investment Management LLC lifted its position in shares of Repligen by 18,449.1% in the 4th quarter. International Assets Investment Management LLC now owns 58,615 shares of the biotechnology company’s stock worth $10,539,000 after purchasing an additional 58,299 shares during the period. Norden Group LLC lifted its position in shares of Repligen by 1,711.6% in the 1st quarter. Norden Group LLC now owns 38,805 shares of the biotechnology company’s stock worth $7,137,000 after purchasing an additional 36,663 shares during the period. Finally, Artemis Investment Management LLP lifted its position in shares of Repligen by 33.8% in the 1st quarter. Artemis Investment Management LLP now owns 167,813 shares of the biotechnology company’s stock worth $30,852,000 after purchasing an additional 42,380 shares during the period. 97.64% of the stock is owned by institutional investors.

Repligen Stock Down 1.6 %

Shares of NASDAQ RGEN traded down $2.28 during trading on Monday, hitting $138.51. The stock had a trading volume of 608,703 shares, compared to its average volume of 613,051. Repligen Co. has a 12 month low of $110.45 and a 12 month high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.24. The company has a market capitalization of $7.74 billion, a PE ratio of 563.18, a PEG ratio of 4.71 and a beta of 0.96. The firm has a fifty day moving average of $135.47 and a two-hundred day moving average of $166.50.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). The company had revenue of $151.31 million during the quarter, compared to analysts’ expectations of $150.06 million. Repligen had a return on equity of 3.95% and a net margin of 2.44%. Repligen’s quarterly revenue was down 17.1% compared to the same quarter last year. During the same period last year, the firm posted $0.64 earnings per share. As a group, equities research analysts forecast that Repligen Co. will post 1.46 EPS for the current fiscal year.

Analyst Ratings Changes

RGEN has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft upgraded shares of Repligen from a “hold” rating to a “buy” rating and dropped their target price for the company from $180.00 to $155.00 in a research report on Wednesday, June 26th. JPMorgan Chase & Co. dropped their target price on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. Finally, Guggenheim initiated coverage on shares of Repligen in a research report on Tuesday, June 18th. They set a “neutral” rating on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $194.00.

Insider Transactions at Repligen

In other news, CEO Anthony Hunt sold 20,072 shares of the stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the sale, the chief executive officer now directly owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, CEO Anthony Hunt sold 20,072 shares of the stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the sale, the chief executive officer now directly owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Martin D. Madaus purchased 1,615 shares of the stock in a transaction dated Friday, June 14th. The stock was purchased at an average cost of $124.94 per share, for a total transaction of $201,778.10. Following the completion of the acquisition, the director now owns 4,613 shares of the company’s stock, valued at approximately $576,348.22. The disclosure for this purchase can be found here. Insiders own 1.20% of the company’s stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.